Skip to main content
OpenTrials
Completed

NCT Number: NCT01254825

The Efficacy of Adductor-Canal-Block (ACB) in Patients After Knee Arthroscopy

The Purpose of this study is to determine whether Adductor-Canal-Block (ACB) is superior to placebo when it comes to analgetic efficacy after Knee-Arthroscopy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Meniscus Lesion Diagnostic Knee Artroscopy Minor Knee Surgery Neurologic Manifestations Pain Pain (Knee) Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Anaesthesiology, Glostrup University Hospital

Glostrup Municipality, Copenhagen, 2600, Denmark

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-80 years
  • Knee-arthroscopy
  • Written consent
  • ASA I-III
  • BMI 19-35

Exclusion criteria

  • Unable to communicate in Danish
  • Allergic reactions toward drugs used in the trial
  • Pregnancy
  • Abuse of alcohol/drugs
  • Daily opioid intake
  • Infection at injection site
  • Can not be mobilised to 5 meters of walk; pre-surgery

Treatment and study plan

Adductor-Canal-Block, Ropivacain

Procedure

Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.

Other names: Naropin (Ropivacain)

Adductor Canal Block, Placebo (saline)

Procedure

Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.

Primary outcomes

  1. Pain-Score (VAS) - patient standing

    Time frame: 2 hours postoperative

    Pain-score messured on a Visual Analog Scale (VAS) 2 hours after adductor canal block. Patient standing. Intervention-group vs. placebo-group.

Secondary outcomes

  1. Pain-score (VAS), patient at rest

    Time frame: 0,1,2,4,6,8,24 hours postoperative

    ACB-group vs. placebo

  2. Pain-score (VAS), patient standing

    Time frame: 1,2,4,6,8,24 hours postoperative

    ACB-group vs. placebo

  3. Pain-score (VAS), after 5 meters of walk

    Time frame: 2,4,6,8,24 hours postoperative

    ACB-group vs. placebo

  4. Total Opioid-consumption

    Time frame: 0-24 hours postoperative

    ACB-group vs. placebo-group

  5. Opioid-consumption, postoperative

    Time frame: 0-2, 2-4, 4-6, 6-8, 8-24 hours postoperative

    i.v. morfin 0-2 hours postoperative tbl. morfin 2-24 hours postoperative ACB vs. placebo

  6. Postoperative Nausea and vomiting

    Time frame: 0-1, 1-2, 2-4, 4-6, 6-8, 8-24 hours postoperative

    Rating-scale 0-3 ACB-group vs. placebo-group

  7. Postoperative ondansetron consumption

    Time frame: In-hospital

    ACB-group vs. placebo-group

  8. Sedation

    Time frame: 0,1,2,4,6,8,24 hours postoperative

    Rating-scale: 0-3 ACB-group vs. placebo-group

Sponsors and collaborators

Lead sponsor

Glostrup University Hospital, Copenhagen

Other

Registry information

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Dec 7, 2010
Registry last updated
Sep 11, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.